B2Gold and Vertex Pharmaceuticals stand out as strong buys, driven by robust fundamentals, sector leadership, and clear ...

The Waltham biotech signs more pharma deals than the average company, and already lists Vertex, Takeda and Biogen as its ...

Vertex Pharmaceuticals' unchanged guidance and disappointing trial outcomes for its investigative pain relief treatment led ...

Biotech Vertex Pharmaceuticals stock tumbled on news of disappointing drug data. CEO Reshma Kewalramani paid nearly $4 ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the Most Profitable Large Cap Stocks to Buy According to Analysts ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

We recently published 10 Big Names Bleed Double Digits. Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) is one of the ...

Vertex Pharmaceuticals’ second quarter 2025 results exceeded Wall Street’s expectations, but the market responded sharply ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $200.0 and $460.0 for Vertex Pharmaceuticals, spanning the last ...

Vertex Pharmaceuticals is catching the eyes of bullish analysts, predicting a robust uptrend. Revenue trends and technical ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $481.56, ...

Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) fell 17.4% in the afternoon session after the company ...